As member of the writing committee for the 2019 ESC/EAS Dyslipidemia Guidelines, Brian Ference highlights the foundation of the guidelines, and new recommendations for CVD risk estimation and treatment goals for LDL-c.
ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.
ESC 2019 The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.